Cidara Therapeutics Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Cidara Therapeutics is a mid-sized biotechnology company based in San Diego, California, focused on antiviral and antifungal discovery and development. It leverages its Cloudbreak platform to create novel DFCs that pair targeted small molecules or peptides with a proprietary human antibody fragment. Its lead candidate, CD388, is a long-acting antiviral intended to provide universal protection against influenza with a single dose by directly inhibiting viral replication.

In 2025, it launched the Phase 3 ANCHOR trial for CD388 ahead of schedule. Cidara has leveraged partnerships to progress its pipeline, including a collaboration with hVIVO Group to provide data supporting CD388's development.

Sign up for free to view info

Company overview Employee directory